Approval · Notice of Compliance 5218 · 1995
PRAVACHOL: Notice of Compliance 5218
Issued July 7, 1995
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5218
- Date
- July 7, 1995
- Company
- Squibb Canada Inc., Division Of Bristol-Myers Squibb Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: reduce the rate of progression of atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total LDL-cholesterol to target levels
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRAVACHOL | Not yet assigned | — |
Medicinal ingredients
- PRAVASTATIN SODIUM 10 MG per TAB
- PRAVASTATIN SODIUM 20 MG per TAB